407 related articles for article (PubMed ID: 35209952)
1. Serum Thioredoxin-80 is associated with age, ApoE4, and neuropathological biomarkers in Alzheimer's disease: a potential early sign of AD.
Goikolea J; Gerenu G; Daniilidou M; Mangialasche F; Mecocci P; Ngandu T; Rinne J; Solomon A; Kivipelto M; Cedazo-Minguez A; Sandebring-Matton A; Maioli S
Alzheimers Res Ther; 2022 Feb; 14(1):37. PubMed ID: 35209952
[TBL] [Abstract][Full Text] [Related]
2. Don't forget about tau: the effects of ApoE4 genotype on Alzheimer's disease cerebrospinal fluid biomarkers in subjects with mild cognitive impairment-data from the Dementia Competence Network.
Benson GS; Bauer C; Hausner L; Couturier S; Lewczuk P; Peters O; Hüll M; Jahn H; Jessen F; Pantel J; Teipel SJ; Wagner M; Schuchhardt J; Wiltfang J; Kornhuber J; Frölich L
J Neural Transm (Vienna); 2022 Jun; 129(5-6):477-486. PubMed ID: 35061102
[TBL] [Abstract][Full Text] [Related]
3. ApoE4 effects on automated diagnostic classifiers for mild cognitive impairment and Alzheimer's disease.
Apostolova LG; Hwang KS; Kohannim O; Avila D; Elashoff D; Jack CR; Shaw L; Trojanowski JQ; Weiner MW; Thompson PM;
Neuroimage Clin; 2014; 4():461-72. PubMed ID: 24634832
[TBL] [Abstract][Full Text] [Related]
4. Thioredoxin-80 is a product of alpha-secretase cleavage that inhibits amyloid-beta aggregation and is decreased in Alzheimer's disease brain.
Gil-Bea F; Akterin S; Persson T; Mateos L; Sandebring A; Avila-Cariño J; Gutierrez-Rodriguez A; Sundström E; Holmgren A; Winblad B; Cedazo-Minguez A
EMBO Mol Med; 2012 Oct; 4(10):1097-111. PubMed ID: 22933306
[TBL] [Abstract][Full Text] [Related]
5. Do Cardiometabolic Risk Factors Influence Amyloid, Tau, and Neuronal Function in APOE4 Carriers and Non-Carriers in Alzheimer's Disease Trajectory?
Femminella GD; Taylor-Davies G; Scott J; Edison P;
J Alzheimers Dis; 2018; 64(3):981-993. PubMed ID: 29966204
[TBL] [Abstract][Full Text] [Related]
6. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
[TBL] [Abstract][Full Text] [Related]
7. ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels.
Steward A; Biel D; Dewenter A; Roemer S; Wagner F; Dehsarvi A; Rathore S; Otero Svaldi D; Higgins I; Brendel M; Dichgans M; Shcherbinin S; Ewers M; Franzmeier N
JAMA Neurol; 2023 Dec; 80(12):1295-1306. PubMed ID: 37930695
[TBL] [Abstract][Full Text] [Related]
8. Apolipoprotein E allele 4 effects on Single-Subject Gray Matter Networks in Mild Cognitive Impairment.
Sanabria-Diaz G; Demonet JF; Rodriguez-Herreros B; Draganski B; Kherif F; Melie-Garcia L
Neuroimage Clin; 2021; 32():102799. PubMed ID: 34469849
[TBL] [Abstract][Full Text] [Related]
9. Influence of plasma matrix metalloproteinase levels on longitudinal changes in Alzheimer's disease (AD) biomarkers and cognitive function in patients with mild cognitive impairment due to AD registered in the Alzheimer's Disease Neuroimaging Initiative database.
Abe K; Chiba Y; Hattori S; Yoshimi A; Asami T; Katsuse O; Suda A; Hishimoto A;
J Neurol Sci; 2020 Sep; 416():116989. PubMed ID: 32603972
[TBL] [Abstract][Full Text] [Related]
10. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
[TBL] [Abstract][Full Text] [Related]
11. The Role of Amyloid, Tau, and APOE Genotype on the Relationship Between Informant-Reported Sleep Disturbance and Alzheimer's Disease Risks.
Kim H; Levine A; Cohen D; Gehrman P; Zhu X; Devanand DP; Lee S; Goldberg TE;
J Alzheimers Dis; 2022; 87(4):1567-1580. PubMed ID: 35491776
[TBL] [Abstract][Full Text] [Related]
12. Head-to-head comparison of plasma p-tau181, p-tau231 and glial fibrillary acidic protein in clinically unimpaired elderly with three levels of APOE4-related risk for Alzheimer's disease.
Snellman A; Ekblad LL; Ashton NJ; Karikari TK; Lantero-Rodriguez J; Pietilä E; Koivumäki M; Helin S; Karrasch M; Zetterberg H; Blennow K; Rinne JO
Neurobiol Dis; 2023 Jul; 183():106175. PubMed ID: 37268240
[TBL] [Abstract][Full Text] [Related]
13. CSF Alzheimer Disease Biomarkers: Time-Varying Relationships With MCI Symptom Onset and Associations With Age, Sex, and
Greenberg BD; Pettigrew C; Soldan A; Wang J; Wang MC; Darrow JA; Albert MS; Moghekar A
Neurology; 2022 Oct; 99(15):e1640-e1650. PubMed ID: 36216518
[TBL] [Abstract][Full Text] [Related]
14. Design and first baseline data of the DZNE multicenter observational study on predementia Alzheimer's disease (DELCODE).
Jessen F; Spottke A; Boecker H; Brosseron F; Buerger K; Catak C; Fliessbach K; Franke C; Fuentes M; Heneka MT; Janowitz D; Kilimann I; Laske C; Menne F; Nestor P; Peters O; Priller J; Pross V; Ramirez A; Schneider A; Speck O; Spruth EJ; Teipel S; Vukovich R; Westerteicher C; Wiltfang J; Wolfsgruber S; Wagner M; Düzel E
Alzheimers Res Ther; 2018 Feb; 10(1):15. PubMed ID: 29415768
[TBL] [Abstract][Full Text] [Related]
15. Injury markers but not amyloid markers are associated with rapid progression from mild cognitive impairment to dementia in Alzheimer's disease.
van Rossum IA; Visser PJ; Knol DL; van der Flier WM; Teunissen CE; Barkhof F; Blankenstein MA; Scheltens P
J Alzheimers Dis; 2012; 29(2):319-27. PubMed ID: 22233766
[TBL] [Abstract][Full Text] [Related]
16. Discordant amyloid-β PET and CSF biomarkers and its clinical consequences.
de Wilde A; Reimand J; Teunissen CE; Zwan M; Windhorst AD; Boellaard R; van der Flier WM; Scheltens P; van Berckel BNM; Bouwman F; Ossenkoppele R
Alzheimers Res Ther; 2019 Sep; 11(1):78. PubMed ID: 31511058
[TBL] [Abstract][Full Text] [Related]
17. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
[TBL] [Abstract][Full Text] [Related]
18. Association of Apolipoprotein E ε4 With Medial Temporal Tau Independent of Amyloid-β.
Therriault J; Benedet AL; Pascoal TA; Mathotaarachchi S; Chamoun M; Savard M; Thomas E; Kang MS; Lussier F; Tissot C; Parsons M; Qureshi MNI; Vitali P; Massarweh G; Soucy JP; Rej S; Saha-Chaudhuri P; Gauthier S; Rosa-Neto P
JAMA Neurol; 2020 Apr; 77(4):470-479. PubMed ID: 31860000
[TBL] [Abstract][Full Text] [Related]
19. Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults.
Popp J; Oikonomidi A; Tautvydaitė D; Dayon L; Bacher M; Migliavacca E; Henry H; Kirkland R; Severin I; Wojcik J; Bowman GL
Brain Behav Immun; 2017 May; 62():203-211. PubMed ID: 28161476
[TBL] [Abstract][Full Text] [Related]
20. Association of Klotho-VS Heterozygosity With Risk of Alzheimer Disease in Individuals Who Carry APOE4.
Belloy ME; Napolioni V; Han SS; Le Guen Y; Greicius MD;
JAMA Neurol; 2020 Jul; 77(7):849-862. PubMed ID: 32282020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
